Synthesis, characterization and antiviral activity against influenza virus of a series of novel manganese-substituted rare earth borotungstates heteropolyoxometalates.
A series of novel manganese-substituted mixed-valence rare earth borotungsto-heteropoly blues, Ln2H3[BW9(VI)W2(V)Mn(H2O)O39] x 12H2O (Ln(2), Ln = La, Ce, Pr, Nd, Sm, Eu and Gd), as well as their corresponding heteropoly acids (Ln(0)), have been prepared and characterized by cyclic voltammetry (CV), infrared (IR), ultraviolet (UV), thermal gravimetric (TG) and differential thermal (DTA) analysis, X-ray photoelectron spectroscopy (XPS) and electrochemistry. It's shown that the heteropoly blues anion in Ln(2) still retains the alpha-Keggin structure but with a slight distortion as heteropoly acids do, and Mn and W atoms distribute statistically in the whole molecular. At the same time, the cell toxicity and antiviral activity of these rare earth borotungstateheteropoly blues against influenza virus type A and type B in MDCK cells have been investigated using plaque reduction assay. The results elucidated that these complexes exhibit a significantly inhibitory activity and almost no cytotoxicity comparable with those obtained from virazole, and the anti-virus activity depend on the structure of these complexes.
Liu
Jie
J
Department of Chemistry, The Key Laboratory of Gene Engineering of Education Ministry, Zhongshan University, Guangzhou 510275, PR China. cesliuj@zsu.edu.cn
Mei
Wen-Jie
WJ
Xu
An-Wu
AW
Tan
Cai-Ping
CP
Shi
Shuo
S
Ji
Liang-Nian
LN
D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003588:Cytopathogenic Effect, Viral; D004285:Dogs; D009980:Influenza A virus / Q000187:drug effects* / Q000254:growth & development; D009981:Influenza B virus / Q000187:drug effects* / Q000254:growth & development; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D010084:Oxidation-Reduction; D012254:Ribavirin / Q000494:pharmacology; D013057:Spectrum Analysis; D013329:Structure-Activity Relationship; D010948:Viral Plaque Assay
D000998:Antiviral Agents; D009942:Organometallic Compounds; D012254:Ribavirin